- Report
- February 2024
- 30 Pages
Global
€3412EUR$3,550USD£2,926GBP
- Report
- March 2024
- 184 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- March 2024
- 198 Pages
Global
From €3243EUR$3,374USD£2,781GBP
€3603EUR$3,749USD£3,090GBP
- Report
- January 2024
- 175 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Report
- January 2024
- 200 Pages
Global
From €4806EUR$5,000USD£4,121GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1442EUR$1,500USD£1,236GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,030GBP
- Report
- February 2024
- 150 Pages
Global
From €4085EUR$4,250USD£3,503GBP
- Report
- November 2023
- 30 Pages
Global
From €2643EUR$2,750USD£2,267GBP
- Report
- March 2024
- 200 Pages
Global
From €3989EUR$4,150USD£3,421GBP
- Report
- January 2023
- 130 Pages
Global
From €5719EUR$5,950USD£4,904GBP
- Report
- August 2022
- 155 Pages
Global
From €7209EUR$7,500USD£6,182GBP
- Report
- January 2022
- 130 Pages
Global
From €6680EUR$6,950USD£5,728GBP
- Report
- January 2022
- 419 Pages
Global
From €9131EUR$9,500USD£7,830GBP
- Report
- April 2023
- 117 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- April 2023
- 115 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- November 2021
- 101 Pages
Global
From €4325EUR$4,500USD£3,709GBP
- Report
- August 2022
- 120 Pages
Global
From €4565EUR$4,750USD£3,915GBP
- Report
- September 2021
- 40 Pages
China
From €2499EUR$2,600USD£2,143GBP
- Report
- April 2021
- 50 Pages
China
From €2499EUR$2,600USD£2,143GBP
Budesonide is a corticosteroid used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It is available in both inhalation and oral forms, and is used to reduce inflammation in the airways. Budesonide is a synthetic corticosteroid, meaning it is similar to the hormones produced naturally by the body. It works by reducing inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath.
Budesonide is a widely used drug in the respiratory market, and is often prescribed as a first-line treatment for asthma and COPD. It is generally well-tolerated and has fewer side effects than other corticosteroids. It is also used in combination with other drugs to treat more severe cases of respiratory diseases.
Some companies in the Budesonide market include AstraZeneca, GlaxoSmithKline, Merck, and Teva Pharmaceuticals. Show Less Read more